Principles for Good Practice in the Conduct of Non-interventional Studies: The View of Industry Researchers

被引:4
作者
Acha, Virginia [1 ]
Barefoot, Bart [2 ]
Garcia, Ariadna Juarez [3 ]
Lehner, Valerie [4 ]
Monno, Raffaella [5 ]
Sandler, Susan [6 ]
Spooner, Almath [7 ]
Verpillat, Patrice [8 ]
机构
[1] MSD, 2 Pancras Sq, London, England
[2] GSK, London, England
[3] BMS, London, England
[4] Servier, Suresnes, Ile De France, France
[5] Chiesi, Parma, Italy
[6] Janssen Cilag Ltd, High Wycombe, England
[7] AbbVie, Dublin, Ireland
[8] Merck Healthcare KGaA, Darmstadt, Germany
关键词
Non-interventional studies; NIS; Good practice; Hypothesis evaluating treatment effect; HETE; Real-world evidence; RWE; Real world data; RWD; REAL-WORLD EVIDENCE; TASK-FORCE; RECOMMENDATIONS; TRANSPARENCY;
D O I
10.1007/s43441-023-00544-y
中图分类号
R-058 [];
学科分类号
摘要
This reflection paper presents a consolidated view of EFPIA on the need for principles for good practice in the generation and use of non-interventional studies (NIS), including overarching principles such as the registration of hypothesis evaluating treatment effect (HETE) studies. We first define NIS and the important adjacencies to clinical trials and relationship with real-world evidence (RWE). We then outline the principles for good practice with respect to appropriate research design, study protocol, fit-for-purpose variables and data quality, analytical methods, bias reduction, transparency in conduct and use, privacy management and ethics review. We conclude with recommendations for action for the research community to promote trust and credibility in the use of NIS.
引用
收藏
页码:1199 / 1208
页数:10
相关论文
共 59 条
[1]  
Andrews E.B., 2015, Guidelines for good pharmacoepidemiology practices (GPP)
[2]  
Aronson JK, 2018, CATALOGUE BIASES
[3]   Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making [J].
Berger, Marc L. ;
Sox, Harold ;
Willke, Richard J. ;
Brixner, Diana L. ;
Eichler, Hans-Georg ;
Goettsch, Wim ;
Madigan, David ;
Makady, Amr ;
Schneeweiss, Sebastian ;
Tarricone, Rosanna ;
Wang, Shirley V. ;
Watkins, John ;
Daniel Mullins, C. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) :1033-1039
[4]   A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report [J].
Berger, Marc L. ;
Martin, Bradley C. ;
Husereau, Don ;
Worley, Karen ;
Allen, J. Daniel ;
Yang, Winnie ;
Quon, Nicole C. ;
Mullins, C. Daniel ;
Kahler, Kristijan H. ;
Crown, William .
VALUE IN HEALTH, 2014, 17 (02) :143-156
[5]   Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms [J].
Burcu, Mehmet ;
Dreyer, Nancy A. ;
Franklin, Jessica M. ;
Blum, Michael D. ;
Critchlow, Cathy W. ;
Perfetto, Eleanor M. ;
Zhou, Wei .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (10) :1228-1235
[6]  
Center for Drug Evaluation and Research, 2021, FDA2021D1214 CTR DRU, P12
[7]  
Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2021, FDA2021D0548, P11
[8]  
Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Oncology Center of Excellence, 2021, FDA2021D1146 CTR DRU, VDraft, P17
[9]  
Clinical Data Interchange Standards Consortium (CDISC), 2022, REAL WORLD DATAREAL
[10]   The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness [J].
Cocoros, Noelle M. ;
Arlett, Peter ;
Dreyer, Nancy A. ;
Ishiguro, Chieko ;
Iyasu, Solomon ;
Sturkenboom, Miriam ;
Zhou, Wei ;
Toh, Sengwee .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (05) :1189-1196